Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
:RDY
RDY Stock Chart & Stats
$13.99
$0.11(0.67%)
At close: 4:00 PM EST
$13.99
$0.11(0.67%)
Day’s Range― - ―
52-Week Range$12.26 - $16.17
Previous CloseN/A
Volume378.64K
Average Volume (3M)1.08M
Market Cap
$11.76B
Enterprise Value$11.58B
Total Cash (Recent Filing)$69.81B
Total Debt (Recent Filing)$58.54B
Price to Earnings (P/E)17.0
Beta0.47
Next Earnings
Jan 23, 2026EPS Estimate
0.17Last Dividend Ex-Date
Jul 25, 2025Dividend Yield0.66%
Share Statistics
EPS (TTM)0.20
Shares Outstanding834,582,150
10 Day Avg. Volume914,421
30 Day Avg. Volume1,084,793
Financial Highlights & Ratios
PEG Ratio10.58
Price to Book (P/B)2.82
Price to Sales (P/S)2.89
P/FCF Ratio78.16
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Dr Reddy's Laboratories News
RDY FAQ
What was Dr. Reddy's Laboratories Ltd’s price range in the past 12 months?
Dr. Reddy's Laboratories Ltd lowest stock price was $12.26 and its highest was $16.17 in the past 12 months.
What is Dr. Reddy's Laboratories Ltd’s market cap?
Dr. Reddy's Laboratories Ltd’s market cap is $11.76B.
When is Dr. Reddy's Laboratories Ltd’s upcoming earnings report date?
Dr. Reddy's Laboratories Ltd’s upcoming earnings report date is Jan 23, 2026 which is in 43 days.
How were Dr. Reddy's Laboratories Ltd’s earnings last quarter?
Dr. Reddy's Laboratories Ltd released its earnings results on Oct 24, 2025. The company reported $0.196 earnings per share for the quarter, beating the consensus estimate of $0.193 by $0.003.
Is Dr. Reddy's Laboratories Ltd overvalued?
According to Wall Street analysts Dr. Reddy's Laboratories Ltd’s price is currently Overvalued.
Does Dr. Reddy's Laboratories Ltd pay dividends?
Dr. Reddy's Laboratories Ltd pays a Annually dividend of $0.091 which represents an annual dividend yield of 0.66%. See more information on Dr. Reddy's Laboratories Ltd dividends here
What is Dr. Reddy's Laboratories Ltd’s EPS estimate?
Dr. Reddy's Laboratories Ltd’s EPS estimate is 0.17.
How many shares outstanding does Dr. Reddy's Laboratories Ltd have?
Dr. Reddy's Laboratories Ltd has 834,582,150 shares outstanding.
What happened to Dr. Reddy's Laboratories Ltd’s price movement after its last earnings report?
Dr. Reddy's Laboratories Ltd reported an EPS of $0.196 in its last earnings report, beating expectations of $0.193. Following the earnings report the stock price went down -0.274%.
Which hedge fund is a major shareholder of Dr. Reddy's Laboratories Ltd?
Currently, no hedge funds are holding shares in RDY
Dr Reddy's Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
RDY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 310.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.01%
12-Months-Change
Fundamentals
Return on Equity
17.72%
Trailing 12-Months
Asset Growth
9.79%
Trailing 12-Months
Company Description
Dr. Reddy's Laboratories Ltd
Dr Reddy's Laboratories (RDY) is a global pharmaceutical company based in India, primarily engaged in the development, manufacture, and marketing of a wide range of pharmaceuticals in various therapeutic areas including oncology, cardiovascular, and pain management. The company operates in several segments including generics, proprietary products, and pharmaceutical services, with a strong focus on research and development to innovate and improve healthcare solutions. Dr Reddy's also offers active pharmaceutical ingredients (APIs) and provides contract manufacturing services, serving both domestic and international markets.
RDY Company Deck
RDY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed performance with significant revenue growth in various markets and strategic acquisitions, contrasted by challenges in the U.S. generics market, regulatory hurdles, and decreased margins.View all RDY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
1.06% Mutual Funds
3.12% Other Institutional Investors
94.97% Public Companies and
Individual Investors